iSpecimen Inc. (ISPC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.02%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.02% | Share-based compensation / revenue. Period ending 2026-06-30. $4.74K ÷ $466.30K × 100 ≈ 1.02% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 466.30K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 4.74K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -9.42M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $466.30K | $4.74K | $-9.42M | (m) | (m) | 1.02% | (m) | (m) |
| 2026-03-31 | (m) | $1.03M | $6.39K | $-9.88M | (m) | (m) | 0.62% | (m) | (m) |
| 2025-12-31 | (m) | $1.93M | $21.27K | $-8.98M | (m) | (m) | 1.10% | (m) | (m) |
| 2025-09-30 | (m) | $3.35M | $30.47K | $-12.13M | (m) | (m) | 0.91% | (m) | (m) |
| 2025-06-30 | (m) | $5.91M | $93.82K | $-11.01M | (m) | (m) | 1.59% | (m) | (m) |
| 2025-03-31 | (m) | $8.06M | $171.65K | $-11.37M | (m) | (m) | 2.13% | (m) | (m) |
| 2024-12-31 | $1.49M | $9.29M | $249.68K | $-12.73M | (m) | 16.07% | 2.69% | (m) | (m) |
| 2024-09-30 | (m) | $10.39M | $346.82K | $-9.76M | $20.77K | (m) | 3.34% | -469.86× | Reported |
| 2024-06-30 | (m) | $10.51M | $387.97K | $-10.25M | $17.87K | (m) | 3.69% | -573.44× | Reported |
| 2024-03-31 | (m) | $9.27M | $433.03K | $-11.63M | $16.93K | (m) | 4.67% | -686.75× | Reported |
| 2023-12-31 | $1.62M | $9.93M | $459.67K | $-11.17M | $16.00K | 16.31% | 4.63% | -698.04× | Reported |
| 2023-09-30 | (m) | $10.31M | $396.69K | $-10.44M | $111.59K | (m) | 3.85% | -93.56× | Reported |
| 2023-06-30 | (m) | $10.12M | $510.33K | $-11.35M | $165.71K | (m) | 5.04% | -68.47× | Reported |
| 2023-03-31 | (m) | $10.83M | $614.98K | $-10.37M | $204.45K | (m) | 5.68% | -50.72× | Reported |
| 2022-12-31 | $1.47M | $10.40M | $678.61K | $-10.19M | $238.96K | 14.17% | 6.52% | -42.63× | Reported |
| 2022-09-30 | (m) | $9.99M | $805.31K | $-10.04M | $179.04K | (m) | 8.06% | -56.07× | Reported |
| 2022-06-30 | (m) | $10.12M | $985.19K | $-8.40M | $196.59K | (m) | 9.73% | -42.71× | Reported |
| 2022-03-31 | (m) | $10.69M | $784.22K | $-7.34M | $1.29M | (m) | 7.34% | -5.70× | Reported |
| 2021-12-31 | $295.31K | $11.14M | $622.06K | $-5.93M | $2.10M | 2.65% | 5.59% | -2.82× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $319.24K | $8.18M | $92.87K | $-2.41M | $2.10M | 3.90% | 1.13% | -1.15× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |